Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

Vainchenker W, Dusa A, Constantinescu SN.

Semin Cell Dev Biol. 2008 Aug;19(4):385-93. doi: 10.1016/j.semcdb.2008.07.002. Epub 2008 Jul 17. Review.

PMID:
18682296
2.

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.

Constantinescu SN, Leroy E, Gryshkova V, Pecquet C, Dusa A.

Biochem Soc Trans. 2013 Aug;41(4):1048-54. doi: 10.1042/BST20130084. Review.

PMID:
23863177
3.

Janus kinases in immune cell signaling.

Ghoreschi K, Laurence A, O'Shea JJ.

Immunol Rev. 2009 Mar;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x. Review.

4.

The use of structural biology in Janus kinase targeted drug discovery.

Alicea-Velázquez NL, Boggon TJ.

Curr Drug Targets. 2011 Apr;12(4):546-55. Review.

5.

Lymphoid malignancies: Another face to the Janus kinases.

Scott LM.

Blood Rev. 2013 Mar;27(2):63-70. doi: 10.1016/j.blre.2012.12.004. Epub 2013 Jan 20. Review.

PMID:
23340138
6.

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L.

J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.

7.

The molecular regulation of Janus kinase (JAK) activation.

Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN.

Biochem J. 2014 Aug 15;462(1):1-13. doi: 10.1042/BJ20140712. Review.

8.

Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.

Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, Fantino E, Rossjohn J, Lucet IS.

J Mol Biol. 2009 Mar 20;387(1):219-32. doi: 10.1016/j.jmb.2009.01.041. Epub 2009 Jan 29.

PMID:
19361440
9.

JAK/STAT signaling in hematological malignancies.

Vainchenker W, Constantinescu SN.

Oncogene. 2013 May 23;32(21):2601-13. doi: 10.1038/onc.2012.347. Epub 2012 Aug 6. Review.

PMID:
22869151
10.

JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.

Treliński J, Robak T.

Curr Med Chem. 2013;20(9):1147-61.

PMID:
23317159
11.

JAK mutations in high-risk childhood acute lymphoblastic leukemia.

Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8. doi: 10.1073/pnas.0811761106. Epub 2009 May 22.

12.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
13.

The Janus kinases (Jaks).

Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ.

Genome Biol. 2004;5(12):253. Epub 2004 Nov 30. Review.

14.

Mining for JAK-STAT mutations in cancer.

Constantinescu SN, Girardot M, Pecquet C.

Trends Biochem Sci. 2008 Mar;33(3):122-31. doi: 10.1016/j.tibs.2007.12.002. Review.

PMID:
18291658
15.

The JAK kinases: not just another kinase drug discovery target.

Wilks AF.

Semin Cell Dev Biol. 2008 Aug;19(4):319-28. doi: 10.1016/j.semcdb.2008.07.020. Epub 2008 Aug 5. Review.

PMID:
18721891
16.

Janus kinases and their role in growth and disease.

Aringer M, Cheng A, Nelson JW, Chen M, Sudarshan C, Zhou YJ, O'Shea JJ.

Life Sci. 1999;64(24):2173-86. Review.

PMID:
10374907
17.

Therapeutic targeting of Janus kinases.

Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ.

Immunol Rev. 2008 Jun;223:132-42. doi: 10.1111/j.1600-065X.2008.00644.x. Review.

18.

The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation.

Holroyd A, Cross NC, Macdonald DH.

Leuk Res. 2011 Oct;35(10):1279-85. doi: 10.1016/j.leukres.2011.05.037. Epub 2011 Jul 1. Review.

PMID:
21722956
19.

Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase.

Behrmann I, Smyczek T, Heinrich PC, Schmitz-Van de Leur H, Komyod W, Giese B, Müller-Newen G, Haan S, Haan C.

J Biol Chem. 2004 Aug 20;279(34):35486-93. Epub 2004 May 3.

20.

A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.

Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP.

PLoS One. 2011;6(5):e19861. doi: 10.1371/journal.pone.0019861. Epub 2011 May 20.

Supplemental Content

Support Center